[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gliomas\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gliomas":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,39,71,106,138,162,185],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100501051","early-phase-1-window-of-opportunity-trial-of-ulixertinib-for-mapk-activated-gliomas-100501051",false,"NCT05804227","Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas","Inclusion criteria:\n\n1. Be willing and able to provide written informed consent for the trial (by participant or legally authorized representative), and assent when applicable. Participants with cognitive impairment will be enrolled. Cognitive function will be assessed by the treating physician or designee through a neurological examination. The formal consent for such participants will be obtained from their legally authorized representative.\n2. Surgical: Be 18 years of age or older on day of signing informed consent. Non-surgical: Be 12 years of age or older on day of signing informed consent.\n\n   \\*Pediatric patients will be dosed at the RP2D of 260mg\u002Fm2 EVERY 12 HRS continuously for 28-day cycles. The pediatric maximal single dose is 450mg. Since the smallest tablet strength of ulixertinib is 150mg, dosing in subjects with a BSA \\\u003C 0.9m2 will be inaccurate. Therefore, only subjects with a BSA of ≥ 0.9m2 are eligible.\n3. MAPK-activated gliomas, mixed glioma or glioneural tumors, including but not limited to those with mutations in BRAF, FGFR, PTPN11, somatic NF-1, NF-1 syndrome-associated gliomas, and recurrent oligodendrogliomas, CIC mutated. Somatic-only NF-1-mutated grade 3, 4 astroctyoma will not be included.\n\n   \\*We will not select for CIC mutation in oligodendrogliomas in the surgical cohort as an inclusion criteria but will check CIC mutation status on the recurrent tissue for two main reasons; 1-CIC mutation is particularly enriched in recurrent OD (Barthel, Johnson et al. 2019) and not newly diagnosed disease, 2- Recurrence happens after more than 10 years and even longer in patients previously treated with radiation and chemotherapy (Bell, Zhang et al. 2020), therefore confirmation of CIC mutation based on archival tissue at the time of diagnosis is very challenging.\n4. Mutational status requires a pathology report, genomic sequencing, or immunohistochemical report of a mutation or activation of the RAS\u002FRAF\u002FMEK\u002FERK pathway.\n5. Prior resection or biopsy with confirmed diagnosis of glioma. Low grade gliomas patients (grade 1, 2) and oligodendroglioma (grade 2, 3) must have had prior radiation OR chemotherapy for the treatment of glioma. High grade glioma patients (grades 3 and 4 excluding oligodendroglioma) must have had prior radiation.\n6. Have the following imaging and surgical criteria:\n\n   1. Surgical: Progressive disease per RANO low-grade glioma or high-grade glioma criteria depending on tumor grade AND presence of respectable tumor are required.\n   2. Non-surgical: Progressive disease per RANO low-grade glioma or high-grade glioma criteria depending on tumor grade.\n7. Patients having undergone radiation are eligible as long as they are at least 12 weeks from radiation with evidence of disease progression per advanced brain tumor imaging \\[(ABTI); includes spectroscopy and perfusion MR studies\\] or biopsy.\n8. Any number of prior relapses.\n9. Be willing to provide tissue from an archival tissue sample.\n10. Presence of archival tissue sample of at least 1 H\\&E and 10 unstained slides. One tissue block will be requested but 10 unstained slides are acceptable if tissue block is not available.\n11. Have a performance status of ≥ 60 on the KPS.\n12. If patient is on steroids, patient must be on a stable or decreasing dose of steroids one week prior to screening MRI. Patients cannot be on more than 16mg of dexamethasone or equivalent per day.\n13. Demonstrate adequate organ function as defined in the Table below. All screening labs should be performed within 14 days (+3 working days) of treatment initiation.\n\n    Organ System - Laboratory Value\n\n    Hematological Absolute neutrophil count (ANC) ≥ 1,500 \u002FmcL\n\n    Platelets ≥ 100,000 \u002FmcL\n\n    Hemoglobin ≥ 9 g\u002FdL or ≥ 5.6 mmol\u002FL\n\n    Renal\n\n    Serum creatinine OR Measured or calculateda creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤1.5 X upper limit of normal (ULN) OR\n\n    ≥ 50 mL\u002Fmin for patient with creatinine levels \\> 1.5 X institutional ULN\n\n    Cardiac\n\n    LVEF ≥ 50%\n\n    Hepatic\n\n    Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for patients with total bilirubin levels \\> 1.5 ULN\n\n    AST (SGOT) and ALT (SGPT) ≤ 3.0 X ULN\n\n    Coagulation International Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN\n\n    \\* Creatinine clearance should be calculated per institutional standard.\n14. Female patients of childbearing potential should have a negative serum pregnancy test within 14 days (+ 3 working days) of study enrollment.\n15. Male and female patients of childbearing potential agree to use highly effective contraception throughout the study and at least 90 days after the last study treatment administration.\n16. Male patients should agree to use an adequate method of contraception during the course of the study and for 90 days after the last dose of the study drug.\n\nExclusion criteria\n\n1. Treatment with bevacizumab less than 3 months prior to enrollment.\n2. Presence of implanted chemotherapy. Previously resected implanted chemotherapy is not excluded.\n3. Less than 12 weeks from completing radiotherapy. Patients with proven progressive disease by biopsy or partial resection or with new lesions outside of the radiation field should not be excluded even if they are within 12 weeks of radiation.\n4. Patient currently participating in a study of an investigational agent or using an investigational device for therapeutic purposes.\n5. Patient has a diagnosis of severe immunodeficiency or is receiving systemic immunosuppressive therapy (except for steroids) within 7 days of study entrance.\n6. Patient has had prior chemotherapy or targeted small molecule therapy, within 3 weeks prior to study Day 1, or has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.\n\n   1. Note: Patients with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study.\n   2. Note: If patient received major surgery (other than craniotomy), they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting therapy.\n7. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.\n8. Has an active infection requiring systemic therapy.\n9. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.\n10. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n11. Is pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit.\n12. Has contraindication for undergoing MRIs.\n13. Is not a candidate for non-emergent surgical resection.\n14. Is taking prohibited concomitant medications (Appendix 5) and is unable to discontinue these medications prior to study enrollment.\n15. A history or current evidence\u002Frisk of retinal vein occlusion or central serous retinopathy","ALL","18 Years",{"count":18,"type":19},40,"ESTIMATED","INTERVENTIONAL",[22],"EARLY_PHASE1","To learn if the study drug, ulixertinib, can cross over the blood-brain barrier in patients with recurrent brain tumors",[25],"Gliomas","RECRUITING","2026-06-10",{"date":29,"type":30},"2026-06-12","ACTUAL",{"date":32,"type":30},"2023-04-20",{"date":34,"type":19},"2027-09-22",{"name":36,"class":37},"M.D. Anderson Cancer Center","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":46,"targetDuration":48,"studyType":49,"phases":4,"briefSummary":50,"conditions":51,"keywords":57,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":38},"100637209","multicenter-prospective-study-on-mri-ai-model-for-midline-glioma-subtyping-and-prognosis-100637209","NCT07608003","Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:","Application of MRI-Based Artificial Intelligence Models for Preoperative Molecular Subtyping and Prognostic Assessment of Midline Gliomas: A Multicenter Prospective Clinical Study","Inclusion Criteria:\n\n* Patients with diffuse gliomas were pathologically and molecularly diagnosed.\n* The clinical case data of all patients were complete.\n* Patients underwent preoperative MRI examination.\n\nExclusion Criteria:\n\n* The tumor is not located in the intracranial midline.\n* Cases in which MRI were incomplete or with significant noise and artifacts.",{"count":47,"type":19},500,"3 Years","OBSERVATIONAL","A vision-language model using preoperative MRI and clinical variables has been developed to simultaneously predict three key molecular markers in midline gliomas: H3K27M, IDH, and 1p\u002F19q. This prospective multicenter study will validate the model's accuracy in preoperative molecular subtyping and its value in prognostic assessment and clinical decision-making across multiple neurosurgical centers.",[52,53,54,55,56,25],"Gliomas Harboring IDH1 and\u002For IDH2 Mutations","Glioma Glioblastoma Multiforme","Glioma of Brainstem","Glioma, Diffuse Midline, H3K27M-mutant","Glioma : Oligodendroglioma or Astrocytoma",[58,59,60,61],"Midline gliomas","Molecular diagnosis","Foundation model","Prognosis prediction","2026-05-25",{"date":64,"type":30},"2026-05-27",{"date":66,"type":19},"2026-05-10",{"date":68,"type":19},"2030-12-31",{"name":70,"class":37},"Xiangya Hospital of Central South University",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":20,"phases":81,"briefSummary":83,"conditions":84,"keywords":90,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":38},"100621751","observational-study-of-responses-to-treatments-in-advanced-central-nervous-system-cns-tumors-100621751","NCT07374692","Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors","* INCLUSION CRITERIA\n* Participants must have advanced CNS tumors confirmed by a documented pathology report, including:\n\n  * recurrent isocitrate dehydrogenase (IDH)-wild-type high-grade glioma\n  * recurrent IDH-mutant gliomas\n  * other recurrent CNS tumors\n* Participants must have been scheduled for a brain tumor biopsy or resection. Note: Scheduled brain tumor biopsy or resection must be at least 6 months after any previous radiation therapy, if applicable. All procedures are planned to take place at NIH.\n* Age \\>= 15 years.\n* Ability of participant, parent\u002Fguardian, or Legally Authorized Representative (LAR) to understand and sign a written informed consent document.\n\nEXCLUSION CRITERIA\n\nNone.","15 Years","120 Years",{"count":80,"type":19},80,[82],"NA","Background:\n\nPrimary central nervous system (CNS) tumors grow in the brain and spinal cord. These tumors are rare, but they are difficult to treat and often fatal. SmartMatch is a new technology that tries to help find the best medicines for the particular tumor by testing how small pieces of surgically removed tumor tissue react to different drugs. The study team wants to see if SmartMatch can complete the analysis and generate a report within 21 days from the time of the surgery.\n\nObjective:\n\nTo better understand CNS tumors so doctors can find better ways to treat them in the future.\n\nEligibility:\n\nPeople aged 15 years and older with recurrent CNS tumors. Patient must already be scheduled for a surgery for the tumor at the NIH.\n\nDesign:\n\nThe study team will collect a small amount of tumor samples during the planned surgery. They may also use tumor samples from previous procedures. No new or additional procedures will be done for the purpose of this study.\n\nThe tumor samples will be sent to a lab for SmartMatch analysis. Once completed, the results will be shared with the patient and his\u002Fher local doctor. Together they can decide whether to incorporate the results into the treatment plan. It is important to know that the results may or may not be helpful.\n\nThere will only be one blood test for research. Blood and tissue samples collected may be used for additional analysis. Tumor tissue may be used to grow additional samples for further study. Participants will receive a pathology diagnosis and mutation profile generated by pathologists who specialize in CNS tumors.\n\nThe study team will seek updates on participant's health approximately every 6 months for 3 years. Tumor samples may also be collected from any additional surgery done at NIH during this time....",[85,86,25,87,88,89],"Recurrent CNS Tumors","Brain Cancer","IDH-wildtype Gliomas","IDH-mutant Gliomas","Rare CNS Tumor",[91,92,93,94,25,95],"CNS Tumor","Brain Tumor","Rare Tumor","SmartMatch","Drug Screen","2026-05-21",{"date":98,"type":30},"2026-05-22",{"date":100,"type":30},"2026-02-04",{"date":102,"type":19},"2030-12-30",{"name":104,"class":105},"National Cancer Institute (NCI)","NIH",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":116,"conditions":117,"keywords":121,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100608184","ai-assisted-diagnosis-of-malignant-brain-tumors-100608184","NCT07198256","AI-assisted Diagnosis of Malignant Brain Tumors","Research on AI-assisted Diagnosis of Common Malignant Brain Tumors Based on Magnetic Resonance Imaging","Inclusion Criteria:\n\n* Patients diagnosed with glioma, brain metastases, and brain lymphoma by pathology, with the patient being at least 18 years old; preoperative MRI was complete.\n\nExclusion Criteria:\n\n* Poor image quality; history of previous brain surgery or radiotherapy; accompanied by other intracranial lesions.","100 Years",{"count":115,"type":19},3000,"This study aims to establish a large-scale, multi-center MRI database for malignant brain tumors. It will develop an artificial intelligence system for the segmentation and classification of multiple subtypes of brain tumors (including glioma, metastatic tumor and lymphoma et al.) using deep learning technology. This will address the issues of small sample sizes and limited classification performance in existing methods, thereby improving the accuracy of non-invasive preoperative diagnosis, reducing the need for biopsies, and having significant clinical translational value.",[25,118,119,120],"Brain Metastases, Adult","Lymphoma","Brain Tumor Adult",[122,123,124,125,126,127],"brain tumor","glioma","brain metastases","lymphoma","magnetic resonance imaging","artificial intelligence","2025-09-22",{"date":130,"type":30},"2025-09-30",{"date":132,"type":30},"2025-09-01",{"date":134,"type":19},"2028-12-31",{"name":136,"class":37},"Second Affiliated Hospital, School of Medicine, Zhejiang University",2,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":15,"minAge":145,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":161},"100590587","a-multicentre-retrospective-prospective-real-world-study-to-evaluate-the-effectiveness-and-safety-of-vorasidenib-in-patients-with-isocitrate-dehydrogenase-idh12-mutant-grade-2-astrocytoma-or-oligodendroglioma-victoria-study-100590587","NCT06969352","A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1\u002F2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)","VICTORIA","Inclusion and exclusion criteria for treatment group\n\nPatients will be included if they meet all the following criteria:\n\n1. Patients (female and male) aged ≥ 12 years at enrolment.\n2. Patients with tissue-confirmed diagnoses of Grade 2 astrocytoma or oligodendroglioma with IDH1 or IDH2 mutation\n3. Have undergone at least one prior glioma surgery (biopsy, subtotal resection, or complete resection).\n4. Patients with evaluable disease based on the most recent MRI in the opinion of the treating physician. A measurable non-enhanced lesion is defined as at least one target lesion with dimensions of ≥1 cm × ≥1 cm (in two dimensions). Confirmed by a centralized IRC as minimal, non-nodular, and non-measurable enhancement.\n5. The PI evaluates based on the Vorasidenib label and patients is willing plan to receive Vorasidenib\n6. Be able to understand and provide written informed consent if the patient is 18 years or older, or if the patient is a minor (12 years or older and under 18 years), both the patient and their legal representative must sign the informed consent.\n\nPatients who meet at least one of the following exclusion criteria will not be included in the study:\n\n1. Patients who received radiotherapy, chemotherapy or other IDH inhibitor for Glioma before enrolment.\n2. Patients with any contrindications to Vorasidenib\n\nInclusion and exclusion criteria for the external control group\n\nPatients will be included if they meet all the following criteria:\n\n1. Patients (female and male) aged ≥ 12 years at the index date.\n2. Patients with tissue-confirmed diagnoses of Grade 2 astrocytoma or oligodendroglioma with IDH1 or IDH2 mutation\n3. Have undergone at least one prior glioma surgery (biopsy, subtotal resection, or complete resection) before the index date.\n4. Since the index date, the patient must have undergone at least two magnetic resonance imaging (MRI) scans with an interval of at least 6 months (±30 days), showing measurable or evaluable non-enhancing lesions. Measurable non-enhancing lesions are defined as at least one target lesion that is ≥1 cm × ≥1 cm (two-dimensional). These lesions must be centrally confirmed by the IRC (Independent Review Committee) as small, non-nodular, and nonmeasurable enhancing lesions.\n\n6\\) Must have at least 6 months (±30 days) follow-up historical data since the index date without any treatment in this period.\n\nPatients who meet at least one of the following exclusion criteria will not be included in the study:\n\n1\\) Patients who received radiotherapy, chemotherapy or other IDH inhibitors for Glioma before the index date.","12 Years",{"count":147,"type":19},60,"The goal of this Study is to evaluate the effectiveness and safety of Vorasidenib in Patients with Isocitrate dehydrogenase IDH1\u002F2 mutant Grade 2 astrocytoma or oligodendroglioma, primary purposeis to evaluate the efficectiveness of Vorasidenib in glioma patients treated in routine clinical practice in In China, patients aged 12 and above with grade II or higher astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations. The main question it aims to answer is:\n\nif this trend is consistent with the efficacy observed in the INDIGO study, and there is not any new safety signal compared to previous research data? Researchers will compare to no treatment. Participants is not mandatory for a formal visit as it is a real-word study.However, due to the fact that patients will be treated with new drugs and need to collect data on major efficacy, regular visits should be performed in routine clinical practice.\n\nThis study is a multicenter, retrospective-and prospective real-world study, There are treatment group (Vorasidenib) and external control group (untreated after surgery).",[25],"NOT_YET_RECRUITING","2025-05-07",{"date":153,"type":30},"2025-05-13",{"date":155,"type":19},"2025-06",{"date":157,"type":19},"2027-02",{"name":159,"class":160},"Servier (Tianjin) Pharmaceutical Co. LTD.","INDUSTRY",3,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":20,"phases":169,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":38},"100579749","early-phase-1-a-single-arm-open-exploratory-clinical-study-of-allogeneic-car-t-cells-in-the-treatment-of-relapsedrefractory-brain-gliomas-with-positive-cd70-expression-100579749","NCT06828341","A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed\u002FRefractory Brain Gliomas With Positive CD70 Expression","Inclusion Criteria:\n\n* 1\\) Agree to follow the study treatment plan and visit plan, voluntarily enroll, and sign the informed consent in writing; 2) Aged ≥18 years old on the day of signing the informed consent, regardless of gender; 3) Patients with recurrent\u002Frefractory glioma who have failed or cannot tolerate standard treatment and whose CD70 expression is confirmed by cytology or histology; 4) According to the results of immunohistochemistry test in a tertiary hospital (if historical tissue samples show CD70 positivity, no retest is required; if historical tissue samples show CD70 negative, a puncture biopsy is required) \\[historical archived tissue samples within 2 years are acceptable\\], the CD70 expression in the tumor site of the subject meets the positive standard, that is, ≥2+; 5) According to the RANO standard (Appendix 1), there is at least one evaluable or measurable lesion; 6) The expected survival period is ≥12 weeks; 7) The baseline Kanofsky performance score (Kanofsky performance score, KPS) score ≥ 70 points; 8) Subjects have adequate organ and bone marrow function and meet the following laboratory test standards: Bone marrow function: absolute neutrophil count (ANC) ≥ 1.5×109\u002FL (1500\u002Fmm3); platelets (PLT) ≥ 90×109\u002FL (1×105\u002Fmm3) (no blood transfusion or use of auxiliary white blood cells and platelets within 14 days before screening); White blood cell count ≥ 3.0×109\u002FL (3000\u002Fmm3); Hemoglobin (HGB) ≥ 9.0 g\u002FdL; Liver function: serum bilirubin (T-Bil) ≤ 1.5 times the upper limit of normal (ULN), Gilbert's syndrome (Gilbert's syndrome) (persistent or recurrent hyperbilirubinemia, manifested as elevated unconjugated bilirubin in the absence of evidence of hemolysis or liver pathology); patients without liver metastasis, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times ULN, patients with liver metastasis, ALT and AST ≤ 5 times ULN; Renal function: serum creatinine ≤ 1.5 times ULN, or creatinine clearance (Ccr) ≥ 50 mL\u002Fmin (Ccr is calculated using the Cockcroft-Gault formula, see Appendix 5); Coagulation function: international normalized ratio (INR) ≤ 1.5 times ULN, activated partial thromboplastin time (APTT) ≤ 1.5 times ULN; 9) The investigator judges that the patient must have fully recovered from the previous treatment toxicity to ≤ Grade 1, except for the following situations: a. Alopecia; b. Pigmentation; c. Late toxicity caused by radiotherapy, which cannot be recovered by the investigator; d. Neurotoxicity of Grade 2 or below caused by platinum (CTCAE 5.0); Fertility-bearing male and female subjects of childbearing age must use effective contraceptive methods from the time they sign the informed consent until at least 6 months after CAR-T administration, and until 2 consecutive PCR tests show that there are no more CAR-T cells in the body. Women of childbearing age include premenopausal women and women within 2 years after menopause. Women of childbearing age must have a negative pregnancy test result within 7 days before the first dose.\n\nExclusion Criteria:\n\n* 1\\) Patients who have received any treatment related to the CD70 target within 3 years; 2) Patients who have received any experimental drug treatment or used experimental devices within 28 days before CAR-T administration; 3) Patients who have received any systemic anti-tumor treatment within 28 days or 5 half-lives (whichever is longer) before CAR-T administration, including systemic chemotherapy, immunotherapy, hormone therapy (excluding glucocorticoids), targeted therapy, systemic immunomodulators (including but not limited to interferon, interleukin 2 and tumor necrosis factor), and received Chinese herbal medicine or Chinese patent medicine with anti-tumor effects within 14 days before CAR-T administration; 4) Patients who have received radiotherapy within three months before administration; 5) Patients who have received other non-CD70 target cell therapy products within two months before administration; 6) Patients who have received other cell therapy products in the past need to undergo RCL testing during the screening period, and patients with positive results in any test; 7) Patients who have received therapeutic doses of glucocorticoids within 14 days before CAR-T administration (however, physiological replacement doses of glucocorticoids are allowed, such as 10 mg\u002Fday prednisone or equivalent); 8) Patients who received oral or intravenous anticoagulation within 7 days before CAR-T cell administration; 9) Patients with other malignant tumors previously or concurrently, with the following exceptions: Carcinoma in situ that has been cured and has no signs of recurrence for at least 3 years before the study; The primary malignant tumor has been completely resected and in complete remission for ≥5 years. 10) History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; 11) Those with immunodeficiency or autoimmune diseases, or those who need to use immunosuppressants; 12) Those who have received live vaccine immunization within 14 days before screening, or those who need to receive live vaccine immunization during the study; 13) Severe or uncontrollable systemic disease or any unstable systemic disease, including but not limited to uncontrolled hypertension, uncontrolled hyperglycemia, hepatic and renal dysfunction or metabolic diseases, central nervous system diseases, etc.; 14) Known severe cardiovascular disease, congenital long QT syndrome, torsades de pointes, myocardial infarction in the past 6 months, or arterial thrombosis, or unstable angina, or congestive heart failure of grade 3 or above (including grade 3) according to the New York Heart Association (NYHA) classification (see Appendix 3), or left ventricular ejection fraction (LVEF) \\\u003C50%, QTc interval \\>450 ms for men and \\>470 ms for women ms; 15) Any one or both of the test results of Treponema pallidum antibody or human immunodeficiency virus (HIV) antibody are positive, cytomegalovirus (CMV) antibody IgM test is positive and CMV DNA titer is more than 2 times higher than the upper limit of normal value; Epstein-Barr virus antibody IgM test is positive and EBV DNA titer is more than 2 times higher than the upper limit of normal value; Hepatitis C virus antibody is positive and hepatitis C virus (HCV) RNA titer is more than 2 times higher than the upper limit of normal value, or active hepatitis B patients (defined as HBsAg positive and peripheral blood HBV DNA titer is more than 2 times higher than the upper limit of normal value); 16) Pregnant or lactating women; The researchers believe that the subjects have other conditions that may affect compliance or are not suitable for participating in this study.",{"count":161,"type":19},[22],"The goal of this clinical trial is to learn if allogeneic CAR-T cells can treat patients with advanced gliomas. The main questions it aims to answer are:\n\nEvaluate the safety of allogeneic CAR-T cells in the treatment of advanced gliomas.\n\nTo evaluate the effectiveness of allogeneic CAR-T cells in the treatment of advanced gliomas and to study its immunological properties in patients.",[25],[173,174,175],"gliomas","car-t","allogeneic","2025-02-10",{"date":178,"type":30},"2025-02-14",{"date":180,"type":30},"2024-06-13",{"date":182,"type":19},"2026-06-30",{"name":184,"class":37},"JIANG LONGWEI",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":194,"conditions":195,"keywords":197,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":38},"100572684","surgical-suction-aspirates-fluorescence-measurement-100572684","NCT06736470","Surgical Suction Aspirates Fluorescence Measurement","ATM GBM","Inclusion Criteria:\n\n* Admitted to neurosurgery department for surgical resection of a potential glioma\n* Aged 18 years old or older\n* Informed consent obtained\n\nExclusion Criteria:\n\n* Patient belongs to the following vulnerable groups: children, pregnant, prisoners or intellectually disabled,,",{"count":193,"type":19},25,"Gliomas are tumors that occur in all ages; they include the most common malign primary central nervous system tumors in developed countries. Gliomas are often aggressive, and their recommended treatment is surgical resection and chemoradiation. Complete tumor removal is challenging because of diffuse cell growth and the proximity of functionally critical tissues. Surgeons use 5-aminolevulinic acid (5-ALA) drug-induced fluorescence to visually detect tumor cells, which improves resection rates and delays tumor progression. Tumor cells are often left unnoticed because of visual obstacles or weak fluorescence, which may lead to local recurrence and reoperations. Surgical suction devices are used to remove cancerous tissues, but so far the suction aspirate tissues have not been routinely used in tissue detection. This single-center observational study compares experts' visual detection of 5-ALA-induced fluorescence and fluorescence detected from the surgical suction waste. The fluorescence from the suction waste will not be reported back to the surgeon.",[25,196],"High-grade Glioma",[198,199,200,201,202],"aspirate tissue monitoring","high-grade glioma","5-ALA","fluorescence-guided surgery","neurosurgery","2024-12-13",{"date":205,"type":30},"2024-12-16",{"date":207,"type":30},"2023-02-07",{"date":209,"type":19},"2026-01-01",{"name":211,"class":37},"Kuopio University Hospital"]